Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: timothy alan morris who wrote (610)	4/30/1998 8:34:00 PM
From: limit	Read Replies (1) \| Respond to of 849

Thanks for the info. See you in the double digits...soon!

To: timothy alan morris who wrote (610)	5/1/1998 1:28:00 AM
From: Alexander Boese	Read Replies (1) \| Respond to of 849

>> I have two neighbors that have a huge Radiation Oncology Practice together. One was telling me that the standard for treatment of bladder cancer in the US was radical cystectomy (removal of the bladder altogether). Thus there is nothing to follow-up on in terms of monitoring for recurrence, (ie, NMP-22). << Trust me, this is not true. American doctors are no more willing to remove someone's bladder than European doctors are. It's only done when there's no other option.